Prof. François-Clément Bidard and Dr Barbara Pistilli share expert insights on the latest TROPION-Breast01 update, presenting the final OS results from the ESMO Virtual Plenary 2025.

 

This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated, inoperable or metastatic HR+/HER2– breast cancer. 

 

In this video, the experts explore: 

  • Mechanism of action of Dato-DXd 
  • TROPION-Breast01 PFS results and safety outcomes 
  • Final overall survival results and their clinical implications 
  • The future outlook for Dato-DXd 

 

Clinical takeaways

 

  • TROPION-Breast01 final OS results did not reach statistical significance; however, subsequent ADC treatment may have influenced survival outcomes
  • The dual primary endpoint of PFS demonstrates a statistically significant and clinically meaningful improvement with Dato-DXd compared with chemotherapy
  • Secondary efficacy and PRO endpoints continued to show a benefit for Dato-DXd in this final analysis

 

Download the Virtual Plenary slides from ESMO's OncologyPro website: www.oncologypro.esmo.org

  • Recognise the efficacy and safety profiles of TROP2-directed ADCs for patients with advanced or metastatic HR+/HER2- BC, and their place in the treatment landscape  
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions  
  • Be able to monitor and manage adverse events associated with ADC therapy 

François-Clément Bidard, MD PhD, is a Professor of Medical Oncology in Paris and Saint-Cloud, France. His clinical work is dedicated to breast cancer care, whereas his translational and clinical research focuses on all forms of liquid biopsy and new therapies to move ahead of cancer resistance.

Prof. François-Clément Bidard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Bidart discloses financial support/sponsorship from AstraZeneca, Daiichi-Sankyo, Caris, Exact Sciences, General Electrics Healthcare, GSK, Inatherys, Lilly, Merck KGaA, Menarini Silicon Biosystems, Menarini/Stemline, Novartis, Pfizer, Prolynx, Rain Oncology, Roche, SAGA Diagnostics, Seagen, Sanofi

Barbara Pistilli, MD is the chair of the breast cancer unit at Gustave Roussy since March 2021. The clinical activity of Breast Cancer Group encloses around 2000 new patients and 700 inclusions in clinical trials, yearly. The goal of the group is to provide groundbreaking and patient-centered strategies that cover all steps from breast cancer prevention to development of innovative treatment strategies and survivorship care. The scientific strategy is driven by the integration between translational and clinical sciences in a limited number of large comprehensive programs, where knowledge in biology drives clinical development and patient samples feed translational research. In this regard, she leads a large translational program focusing on identification of mechanisms of response and resistance to antibody drug conjugates which include a number of phase I and II trials based on diverse treatment strategies in patients with metastatic breast and lung cancer, with a large sample collection for exploratory biomarker analysis.

Dr Barbara Pistilli has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Seagen, Gilead, Novartis, Lilly, MSD, Pierre Fabre, Daiichi Sankyo, Olema and Pfizer

Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

Experts
Prof. Nicolas Girard
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
ISLB Lung Cancer Europe
  • clock 1 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.